Identification

Name
Dicyclomine
Accession Number
DB00804  (APRD00113)
Type
Small Molecule
Groups
Approved
Description

A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms. [PubChem]

Structure
Thumb
Synonyms
  • 2-(Diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate
  • Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl ester
  • Dicicloverina
  • DICYCLOMINE
  • Dicycloverin
  • Dicycloverine
  • Dicycloverinum
Product Ingredients
IngredientUNIICASInChI Key
Dicyclomine HydrochlorideCQ903KQA3167-92-5GUBNMFJOJGDCEL-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BentylCapsule10 mg/1OralAptalis Pharma Inc.1950-05-11Not applicableUs
BentylTablet20.6 mg/1OralAptalis Pharma Inc.1950-05-11Not applicableUs
BentylInjection, solution20 mg/2mLIntramuscularAptalis Pharma Inc.1952-08-13Not applicableUs
BentylolSyrup10 mgOralAptalis Pharma Canada Ulc1993-12-31Not applicableCanada
Bentylol Dospan 30mgTablet, extended release30 mgOralMerrell Pharms Inc., Division Of Merrell Dow (Can)1988-03-231996-09-09Canada
Bentylol Inj 10mg/mlLiquid10 mgIntramuscularMerrell Pharms Inc., Division Of Merrell Dow (Can)1965-12-311996-09-09Canada
Bentylol Tablet 10mgTablet10 mgOralAptalis Pharma Inc.1995-12-31Not applicableCanada
Bentylol Tablet 20mgTablet20 mgOralAptalis Pharma Inc.1995-12-31Not applicableCanada
Dicyclomine Cap 10mgCapsule10 mgOralDuchesnay Inc.1978-12-312003-07-18Canada
Dicyclomine Hydrochloride Injection USPSolution10 mgIntramuscularSandoz Canada Incorporated1976-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DicyclomineTablet20 mg/1OralWest Ward Pharmaceutical1996-10-01Not applicableUs
DicyclomineCapsule10 mg/1OralRebel Distributors1997-02-28Not applicableUs
DicyclomineTablet20 mg/1Oralbryant ranch prepack1996-10-01Not applicableUs
DicyclomineTablet20 mg/1OralGolden State Medical Supply1996-10-01Not applicableUs
DicyclomineTablet20 mg/1OralMajor1996-10-01Not applicableUs
DicyclomineTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1996-10-01Not applicableUs
DicyclomineTablet20 mg/1OralA S Medication Solutions1996-10-012017-06-20Us
DicyclomineTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.1996-10-01Not applicableUs
DicyclomineTablet20 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs00143 1227 01 nlmimage10 c123608b
DicyclomineTablet20 mg/1OralStat Rx USA1996-10-01Not applicableUs
International/Other Brands
Byclomine / Di-Spaz / Dibent / Dilomine / Dyspas (Savage) / Merbentyl (Sanofi)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
DiclophenDicyclomine Hydrochloride (10 mg) + Phenobarbital (15 mg)CapsuleOralPro Doc Limitee1970-12-312009-07-23Canada
Spasmo Nil TabDicyclomine Hydrochloride (2.5 mg) + Aluminum hydroxide (75 mg) + Dimethicone (7.5 mg) + Magnesium Trisilicate (75 mg)TabletOralDuchesnay Inc.1978-12-312003-07-18Canada
Categories
UNII
4KV4X8IF6V
CAS number
77-19-0
Weight
Average: 309.4867
Monoisotopic: 309.266779369
Chemical Formula
C19H35NO2
InChI Key
CURUTKGFNZGFSE-UHFFFAOYSA-N
InChI
InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3
IUPAC Name
2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate
SMILES
CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1

Pharmacology

Indication

For the treatment of functional bowel/irritable bowel syndrome including Colicky abdominal pain; diverticulitis

Structured Indications
Pharmacodynamics

Dicyclomine is an anticholinergic drug, a medication that reduces the effect of acetylcholine, a chemical released from nerves that stimulates muscles, by blocking the receptors for acetylcholine on smooth muscle (a type of muscle). It also has a direct relaxing effect on smooth muscle. Dicyclomine is used to treat or prevent spasm in the muscles of the gastrointestinal tract in the irritable bowel syndrome. In addition, Dicyclomine inhibits gastrointestinal propulsive motility and decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretions.

Mechanism of action

Action is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and (2) a direct effect upon smooth muscle (musculotropic).

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
Absorption
Not Available
Volume of distribution
  • 3.65 L/kg [20 mg oral dose]
Protein binding

>99%

Metabolism
Not Available
Route of elimination

The principal route of elimination is via the urine (79.5% of the dose). Excretion also occurs in the feces, but to a lesser extent (8.4%).

Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Dicyclomine.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Dicyclomine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Atracurium.Experimental
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dicyclomine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dicyclomine.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Dicyclomine.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dicyclomine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Dicyclomine.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Dicyclomine.Experimental
Botulinum Toxin Type ADicyclomine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BDicyclomine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Carfentanil.Illicit, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Dicyclomine.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Chlorphenoxamine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Dicyclomine.Approved
CimetropiumDicyclomine may increase the anticholinergic activities of Cimetropium.Experimental
CodeineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Dicyclomine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dicyclomine.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dicyclomine.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Desloratadine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dicyclomine.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Dichlorvos.Vet Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Dicyclomine is combined with DPDPE.Investigational
DronabinolDicyclomine may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Edrophonium.Approved
EluxadolineDicyclomine may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Emepronium.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dicyclomine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Fesoterodine.Approved
GalantamineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Dicyclomine.Approved
Ginkgo bilobaThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Glucagon recombinant.Approved
GlycopyrroniumDicyclomine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Dicyclomine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Dicyclomine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dicyclomine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Dicyclomine.Approved
IpidacrineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dicyclomine.Approved
IsoflurophateThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Dicyclomine.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Ketobemidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dicyclomine.Approved
MefloquineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Methantheline.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Dicyclomine.Approved
Methyl salicylateThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MetixeneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Dicyclomine.Approved
MianserinMianserin may increase the anticholinergic activities of Dicyclomine.Approved
MinaprineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Morphine.Approved, Investigational
NabiloneDicyclomine may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dicyclomine.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Otilonium.Experimental
OxitropiumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dicyclomine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pancuronium.Approved
ParaoxonThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Paraoxon.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Dicyclomine.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dicyclomine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Dicyclomine.Approved
Potassium ChlorideDicyclomine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Dicyclomine.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dicyclomine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dicyclomine.Approved
PropiverineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Propiverine.Investigational
PyridostigmineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Dicyclomine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Quinidine.Approved
RamosetronDicyclomine may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dicyclomine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Scopolamine butylbromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Dicyclomine.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Solifenacin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Dicyclomine.Approved
TacrineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tilidine.Experimental
TiotropiumDicyclomine may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Dicyclomine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dicyclomine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Trimethaphan.Approved
TropatepineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dicyclomine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Dicyclomine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Dicyclomine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Vecuronium.Approved
Food Interactions
  • Avoid alcohol.
  • Take this medication 30 minutes before meals.

References

Synthesis Reference

Van Campen, M.G. Jr. and Tilford, C.H.; US.Patent 2,474,796; June 28, 1949; assigned to The Wm. S. Merrell Company.

General References
Not Available
External Links
Human Metabolome Database
HMDB14942
KEGG Compound
C06951
PubChem Compound
3042
PubChem Substance
46505371
ChemSpider
2934
BindingDB
50010101
ChEBI
4514
ChEMBL
CHEMBL1123
Therapeutic Targets Database
DAP001118
PharmGKB
PA164744928
IUPHAR
355
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Dicyclomine
ATC Codes
A03AA07 — Dicycloverine
AHFS Codes
  • 12:08.00 — Anticholinergic Agents
  • 12:08.08 — Antimuscarinics Antispasmodics
FDA label
Download (230 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Axcan pharma us inc
  • Lannett co inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Pioneer pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Bedford laboratories div ben venue laboratories inc
  • Alpharma us pharmaceuticals division
  • Mikart inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular20 mg/2mL
TabletOral20.6 mg/1
SyrupOral10 mg
Tablet, extended releaseOral30 mg
LiquidIntramuscular10 mg
TabletOral10 mg
TabletOral20 mg
CapsuleOral
TabletOral20 mg/1
CapsuleOral10 mg/1
InjectionIntramuscular10 mg/mL
SolutionOral10 mg/5mL
SyrupOral10 mg/mL
TabletOral10 mg/1
SolutionIntramuscular10 mg
CapsuleOral10 mg
TabletOral
Prices
Unit descriptionCostUnit
Bentyl 10 mg/ml ampul12.28USD ml
Dicyclomine 10 mg/ml vial8.58USD ml
Dicyclomine Hydrochloride 10 mg/ml3.41USD ml
Dicyclomine hcl powder1.0USD g
Bentyl 10 mg capsule0.79USD capsule
Bentyl 20 mg tablet0.75USD tablet
Dicyclomine HCl 10 mg capsule0.47USD capsule
Dicyclomine HCl 20 mg tablet0.4USD tablet
Dicyclomine 20 mg tablet0.31USD tablet
Bentylol 20 mg Tablet0.23USD tablet
Bentyl 10 mg/5ml Syrup0.15USD ml
Bentylol 10 mg Tablet0.12USD tablet
Dicyclomine HCl 10 mg/5ml Solution0.1USD ml
Bentylol 2 mg/ml Syrup0.06USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)165-166Van Campen, M.G. Jr. and Tilford, C.H.; US.Patent 2,474,796; June 28, 1949; assigned to The Wm. S. Merrell Company.
logP5.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00327 mg/mLALOGPS
logP5.82ALOGPS
logP4.93ChemAxon
logS-5ALOGPS
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity91.78 m3·mol-1ChemAxon
Polarizability37.39 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.9769
Caco-2 permeable+0.6616
P-glycoprotein substrateSubstrate0.6141
P-glycoprotein inhibitor INon-inhibitor0.6115
P-glycoprotein inhibitor IINon-inhibitor0.5806
Renal organic cation transporterInhibitor0.5184
CYP450 2C9 substrateNon-substrate0.8373
CYP450 2D6 substrateNon-substrate0.8226
CYP450 3A4 substrateSubstrate0.5092
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6193
Ames testNon AMES toxic0.8524
CarcinogenicityNon-carcinogens0.52
BiodegradationNot ready biodegradable0.9876
Rat acute toxicity3.1919 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.873
hERG inhibition (predictor II)Inhibitor0.6714
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0109000000-67a7b4058325a5b3b7b5

Taxonomy

Description
This compound belongs to the class of organic compounds known as carboxylic acid esters. These are carboxylic acid derivatives in which the carbon atom from the carbonyl group is attached to an alkyl or an aryl moiety through an oxygen atom (forming an ester group).
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Carboxylic acid derivatives
Direct Parent
Carboxylic acid esters
Alternative Parents
Trialkylamines / Amino acids and derivatives / Monocarboxylic acids and derivatives / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Tertiary aliphatic amine / Tertiary amine / Carboxylic acid ester / Amino acid or derivatives / Monocarboxylic acid or derivatives / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
tertiary amine, carboxylic ester (CHEBI:4514)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Jin CH, Shin EJ, Park JB, Jang CG, Li Z, Kim MS, Koo KH, Yoon HJ, Park SJ, Choi WC, Yamada K, Nabeshima T, Kim HC: Fustin flavonoid attenuates beta-amyloid (1-42)-induced learning impairment. J Neurosci Res. 2009 Dec;87(16):3658-70. doi: 10.1002/jnr.22159. [PubMed:19533734]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Pavia J, Munoz M, Jimenez E, Martos F, Gonzalez-Correa JA, De la Cruz JP, Garcia V, Sanchez de la Cuesta F: Pharmacological characterization and distribution of muscarinic receptors in human placental syncytiotrophoblast brush-border and basal plasma membranes. Eur J Pharmacol. 1997 Feb 12;320(2-3):209-14. [PubMed:9059856]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:25